Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Rangering i aksjer #39915
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Aksjekurs
$0.00366968
Sist synkronisert: 2024-07-12
Markedsverdi
$299.46K
Endring (1 dag)
-66.77%
Endring (1 år)
0.00%
Land
CA
Handel Biocure Technology Inc. (CURE)

Kategori

Inntekter for Biocure Technology Inc. (CURE)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Biocure Technology Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Biocure Technology Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE